Mechanical Circulatory Support Devices Market By Device Type (Temporary (Acute) MCS Devices (Intra-Aortic Balloon Pumps (IABP); Impella Devices (Percutaneous Ventricular Assist Devices); Extracorporeal Membrane Oxygenation (ECMO) (VA-ECMO, VV-ECMO); CentriMag & Other Percutaneous Pumps (TandemHeart, etc.)); Long-Term (Chronic) MCS Devices (Ventricular Assist Devices (VADs); Left Ventricular Assist Devices (LVADs); Right Ventricular Assist Devices (RVADs); Biventricular Assist Devices (BIVADs); Total Artificial Heart (TAH))); By Application (Hemodynamic Support in Acute Cardiovascular Events; Post-Surgical & Temporary Support; Bridge Therapy for Chronic Heart Failure Patients; Destination Therapy (Long-term Support); Other Specialized Applications); By End-User (Hospitals; Specialty Cardiac Centers; Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Mechanical Circulatory Support (MCS) Devices Market Size & Overview

The Mechanical Circulatory Support (MCS) Devices Market was valued at approximately $4.5 billion in 2024 and is projected to reach $9.8 billion by 2030, growing at a CAGR of 13.2% during the forecast period. The market's expansion is driven by the increasing prevalence of end-stage heart failure (ESHF), advancements in MCS technology, and a growing geriatric population at risk of cardiovascular diseases (CVDs).

 

MCS devices are critical life-saving technologies used to provide temporary or long-term circulatory support in patients with severe cardiac dysfunction. These devices include ventricular assist devices (VADs), intra-aortic balloon pumps (IABPs), percutaneous ventricular assist devices (pVADs), extracorporeal membrane oxygenation (ECMO), and total artificial hearts (TAHs). The rising demand for minimally invasive and percutaneous MCS devices such as Impella by Abiomed (a Johnson & Johnson company) and ECMO for acute cardiovascular conditions, high-risk percutaneous coronary interventions (PCI), and bridge-to-transplant therapy is further accelerating market growth.

 

North America dominated the market in 2024, owing to well-established healthcare infrastructure, increasing adoption of MCS devices in heart failure management, and favorable reimbursement policies. However, Asia-Pacific is expected to witness the highest growth rate due to rising healthcare investments, increasing heart failure prevalence & improving accessibility to advanced cardiovascular care.

 

Despite the promising growth trajectory, challenges such as high costs of implantation, device-related complications (e.g., bleeding, infections, and thrombosis), and limited reimbursement policies in developing regions may hinder widespread adoption. However, continuous innovations in fully implantable LVADs, wireless energy transmission technologies, and biocompatible artificial hearts are expected to drive future market expansion, offering more effective and safer solutions for patients with severe heart failure.

 

Mechanical Circulatory Support (MCS) Devices Market Dynamics:

Rising Prevalence of End-Stage Heart Failure (ESHF) and Cardiogenic Shock

The increasing incidence of heart failure (HF) and cardiovascular diseases (CVDs) globally is a major driver for the MCS devices market. According to the 2022 AHA/ACC/HFSA guideline for the management of heart failure, a person with end stage heart failure typically has stage D, NYHA class IV heart failure. According to the American Heart Association, nearly 6.2 million adults in the U.S. were living with heart failure in 2023 & this number is expected to rise due to aging populations & lifestyle-related risk factors such as hypertension, obesity & diabetes. Mechanical circulatory support devices, such as left ventricular assist devices (LVADs) & extracorporeal membrane oxygenation (ECMO), provide life-saving treatment for patients in end-stage heart failure or acute cardiogenic shock, where pharmacological interventions alone are insufficient. The demand for durable LVADs for destination therapy (DT) & bridge-to-transplant (BTT) patients is expected to surge as heart transplant shortages persist.

Advancements in Miniaturized & Less Invasive MCS Devices

Innovations in minimally invasive mechanical circulatory support devices are transforming the market by improving patient outcomes & reducing complications. The development of smaller, fully implantable LVADs like Medtronic's HVAD System & Abbott’s HeartMate 3 LVAD with magnetically levitated (MagLev) technology has led to reduced hemolysis, lower thromboembolic events & improved durability. Percutaneous ventricular assist devices (pVADs), such as Abiomed’s Impella series, provide short-term hemodynamic support in high-risk percutaneous coronary interventions (PCI) & acute decompensated heart failure (ADHF), driving adoption in interventional cardiology. These technological advancements are enhancing device safety, extending patient life expectancy & expanding indications, fueling market growth.

 

Market Opportunities

Increasing Adoption of Mechanical Circulatory Support in Emerging Markets

The MCS devices market is witnessing substantial growth potential in emerging economies such as China, India & Brazil, where the burden of cardiovascular diseases is escalating. According to the World Health Organization (WHO), over 80% of cardiovascular deaths occur in low & middle-income countries, yet access to advanced cardiac support therapies remains limited. With improving healthcare infrastructure, rising disposable incomes, and increased government investments in tertiary cardiac care, demand for short-term and durable MCS devices is expected to grow. For instance, China’s National Medical Products Administration (NMPA) recently approved Abbott’s HeartMate 3 LVAD, expanding access to advanced mechanical circulatory support solutions in the Asia-Pacific region.

Rising Clinical Trials and R&D for Next-Generation Artificial Hearts

The development of next-generation total artificial hearts (TAHs) and advanced ventricular assist devices (VADs) presents lucrative growth opportunities for market players. Companies such as Carmat (France) & SynCardia Systems (U.S.) are conducting pivotal clinical trials for novel biocompatible artificial heart systems, aimed at providing long-term hemodynamic support for patients ineligible for heart transplantation. For example, Carmat’s Aeson® Total Artificial Heart received CE Mark approval in Europe and is undergoing further trials in the U.S. and Japan. Similarly, biodegradable polymer-based MCS devices & gene therapy-based myocardial recovery approaches hold promise for future advancements, attracting significant venture capital & government funding in cardiovascular research.

 

Market Restraints

High Cost of MCS Devices and Limited Reimbursement Policies

The prohibitive cost of mechanical circulatory support devices remains a major barrier to market expansion. Implantable LVADs & TAHs can cost between $100,000 - $250,000 per patient, excluding hospitalization & follow-up care expenses. In emerging markets, the lack of adequate reimbursement coverage further limits patient access. In India, while heart failure-related treatments are covered under government health schemes, LVAD implantation remains unaffordable for the majority of patients due to limited insurance support. Even in developed markets, reimbursement varies across healthcare systems, with out-of-pocket costs acting as a significant deterrent for adoption.

Device-Related Complications and Risk of Infections

Despite technological advancements, thrombosis, bleeding events, infection risks, and pump failure remain key challenges in mechanical circulatory support therapy. LVAD patients, for example, require long-term anticoagulation therapy, which increases the risk of gastrointestinal bleeding & stroke. According to clinical studies, thromboembolic events occur in up to 20% of LVAD recipients, while driveline infections are reported in nearly 30% of cases. Efforts to develop fully implantable wireless-powered VADs aim to address these risks, but widespread adoption is still in its early stages. Until these challenges are mitigated, clinicians may be hesitant to expand the use of MCS devices beyond severe cases, limiting market penetration.

 

Mechanical Circulatory Support (MCS) Devices Market Segmentation: A Comprehensive Overview

By Device Type

• Temporary (Acute) MCS Devices

  • Intra-Aortic Balloon Pumps (IABP)

  • Impella Devices (Percutaneous Ventricular Assist Devices)

  • Extracorporeal Membrane Oxygenation (ECMO) (VA-ECMO, VV-ECMO)

  • CentriMag & Other Percutaneous Pumps (TandemHeart, etc.)

• Long-Term (Chronic) MCS Devices

  • Ventricular Assist Devices (VADs)

  • Left Ventricular Assist Devices (LVADs)

  • Right Ventricular Assist Devices (RVADs)

  • Biventricular Assist Devices (BIVADs)

  • Total Artificial Heart (TAH)

 

By Application

• Hemodynamic Support in Acute Cardiovascular Events

• Post-Surgical & Temporary Support

• Bridge Therapy for Chronic Heart Failure Patients

• Destination Therapy (Long-term Support)

• Other Specialized Applications

 

By End-User

• Hospitals

• Specialty Cardiac Centers

• Ambulatory Surgical Centers

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Mechanical Circulatory Support (MCS) Devices Market Segment Analysis: Growth Trends Across Categories

By Device Type:

Leading Segment: Long-Term (Chronic) MCS Devices

The long-term mechanical circulatory support (MCS) devices segment, particularly Ventricular Assist Devices (VADs) such as Left Ventricular Assist Devices (LVADs), holds the largest market share. This is due to the increasing prevalence of chronic heart failure (CHF), which necessitates long-term cardiac support. LVADs are commonly used as bridge-to-transplant solutions and in patients who are not candidates for heart transplants. The market share of this segment is approximately 55-60% of the total MCS devices market. The growing demand for VADs is largely driven by the aging population, the rising incidence of heart disease & advancements in device technology that offer improved performance & durability.

Fastest-Growing Segment: Temporary (Acute) MCS Devices

The temporary MCS devices segment is expected to grow at a CAGR of 7-9%. This growth is driven by the increasing demand for acute cardiovascular event management, including cardiogenic shock, acute decompensated heart failure (ADHF), and post-surgical recovery. Devices like Impella and ECMO are gaining traction due to their high efficacy in providing immediate circulatory support. The rising number of patients requiring emergency intervention & post-surgical support is pushing this segment to expand rapidly. Additionally, advancements in percutaneous technology are making these devices more accessible & less invasive, further contributing to their growth.

 

By Application:

Leading Segment: Hemodynamic Support in Acute Cardiovascular Events

Hemodynamic support in acute cardiovascular events, including cardiogenic shock and ADHF, is the leading application segment for MCS devices, accounting for 45-50% of the market share. The rising incidence of cardiovascular diseases, such as heart attacks & severe heart failure, has led to an increased demand for MCS devices to stabilize patients in critical conditions. Technologies like ECMO and Impella are widely used in emergency settings, making this application the dominant one in the market.

Fastest-Growing Segment: Bridge Therapy for Chronic Heart Failure Patients

The "Bridge to Transplant" & "Bridge to Recovery" applications are the fastest-growing in the MCS market, expected to grow at a CAGR of 6-8%. These therapies are especially important for patients waiting for heart transplants or recovering from severe heart failure. The growing transplant waitlist and improvements in the technology of VADs are contributing to this rapid growth. As heart transplant numbers remain limited, the demand for bridge therapies as long-term heart failure solutions is expected to continue expanding.

 

By End-User:

Leading Segment: Hospitals

Hospitals, particularly those with dedicated cardiac care units, make up the largest share of the MCS devices market, holding approximately 60-65% of the total market. This is because hospitals are primary providers of critical care for patients experiencing acute cardiovascular events or those requiring surgical interventions. The increasing number of hospitals equipped with advanced MCS technologies is contributing to the dominance of this segment.

Fastest-Growing Segment: Specialty Cardiac Centers

Specialty cardiac centers are experiencing the fastest growth, projected to grow at a CAGR of 9-11%. These centers specialize in heart disease treatments, including heart failure & transplant services, where MCS devices are in high demand. The shift toward more specialized care, coupled with the growth of cardiac care-focused centers globally, is driving this segment's rapid expansion.

 

By Region:

Leading Region: North America

North America remains the leading region for the MCS devices market, with a market share of approximately 35-40%. The presence of advanced healthcare infrastructure, high adoption rates of new technologies, and significant research and development investments in the U.S. and Canada contribute to this dominance. Additionally, the rising number of heart disease cases & the increasing adoption of MCS devices for both acute and chronic cardiovascular conditions are driving market growth in this region.

Fastest-Growing Region: Asia-Pacific

The APAC region is experiencing the fastest growth in the MCS devices market, projected to grow at a CAGR of 8-10%. Countries like China, Japan & India are seeing an increase in heart disease cases, which is driving the demand for MCS devices. Growing healthcare infrastructure, government investments in medical technologies, and improving access to cardiac care are key factors contributing to the expansion of the MCS market in this region.

 

Key Players in the Mechanical Circulatory Support (MCS) Devices Market

• Abbott Laboratories

• Medtronic plc

• Abiomed, Inc.

• Getinge AB

• Berlin Heart GmbH

• ReliantHeart, Inc.

• LivaNova PLC

• Terumo Corporation

• Jarvik Heart, Inc.

• CorWave SA

 

Mechanical Circulatory Support Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 2.51 Billion
Revenue Forecast in 2030	USD 4.26 Billion
Overall Growth Rate	CAGR of 9.2% (2024 – 2030)
Base Year for Estimation	2023
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2032)
Segmentation	By Device Type, By Application, By End User, By Geography
By Device Type	Temporary (Acute) MCS Devices (Intra-Aortic Balloon Pumps (IABP); Impella Devices (Percutaneous Ventricular Assist Devices); Extracorporeal Membrane Oxygenation (ECMO) (VA-ECMO, VV-ECMO); CentriMag & Other Percutaneous Pumps (TandemHeart, etc.)); Long-Term (Chronic) MCS Devices (Ventricular Assist Devices (VADs); Left Ventricular Assist Devices (LVADs); Right Ventricular Assist Devices (RVADs); Biventricular Assist Devices (BIVADs); Total Artificial Heart (TAH))
By Application	Hemodynamic Support in Acute Cardiovascular Events; Post-Surgical & Temporary Support; Bridge Therapy for Chronic Heart Failure Patients; Destination Therapy (Long-term Support); Other Specialized Applications
By End User	Hospitals; Specialty Cardiac Centers; Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Increasing prevalence of heart failure, advancements in ventricular assist devices, rising adoption of ECMO, growing demand for destination therapy
Pricing and Purchase Options	Customized options available

 

Recent Developments

• On August 21, 2024, Abbott announced a significant advancement in heart failure management by introducing an aspirin-free regimen for patients receiving the HeartMate 3™ Left Ventricular Assist Device (LVAD). The HeartMate 3™ is an implantable device that assists the heart in pumping blood throughout the body in individuals with weakened heart function. This development aims to reduce bleeding complications associated with aspirin use, thereby improving patient outcomes & quality of life. 

• In October 2022, Abiomed received pre-market approval from the U.S. Food & Drug Administration (FDA) for its Impella RP Flex with SmartAssist device. This heart pump is designed to provide temporary percutaneous ventricular support for patients experiencing acute right heart failure or decompensation following procedures such as left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.

• In June 2021, Medtronic completed the acquisition of HeartWare International, a company specializing in less-invasive, miniaturized, mechanical circulatory support technologies for treating patients with advanced heart failure. HeartWare's flagship product, the HVAD System, is among the world's smallest full-support ventricular assist devices, designed to be implanted in the pericardial space. This acquisition aimed to enhance Medtronic's portfolio of diagnostic tools, therapies & services for patients suffering from heart failure.

 

Future Outlook

The future outlook for the Mechanical Circulatory Support (MCS) Devices Market is highly promising, driven by the rising prevalence of heart failure, advancements in device technology & increasing adoption of minimally invasive cardiac assist solutions. The growing burden of end-stage heart failure (HF) and cardiogenic shock has led to a surge in demand for ventricular assist devices (VADs), intra-aortic balloon pumps (IABP), and extracorporeal membrane oxygenation (ECMO) systems. Innovations in miniaturization, fully implantable VADs & percutaneous MCS devices are improving patient outcomes, reducing complications, and expanding treatment options for high-risk patients. Additionally, increasing awareness and expanding heart failure management programs in emerging economies are expected to drive market growth. However, challenges such as high costs, regulatory hurdles & complications related to long-term implantation may hinder widespread adoption. Despite these barriers, ongoing clinical research, strategic collaborations between healthcare providers & manufacturers, and advancements in battery technology, biocompatibility & wireless power transmission will further enhance the market’s potential, making MCS devices a critical component in the future of advanced heart failure management.